S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma

Li, G; Barthélémy, Amélie; Feng, Gang; Gentil-Perret, Anne; Péoc’h, Michel; Genin, Christian; Tostain, Jacques

doi:10.1111/j.1365-2559.2007.02655.x

Cited by 73 publications

(57 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lot has been published in relation to the diagnostic differential between the ChRCC and the RO, with multiple works that demonstrate differences between expression markers in both tumors, however most of them correspond to markers with little diffusion or infrequent use in the anatomic-pathological routine. Among them are S100-A1, Claudins 7 and 8, Endogenous Abidin binding, PAX2, RON, LMP2, Cytochrome C Oxidase and others [10][11][12][13][14][15]. However, data suggests that a set of markers is much better that a single marker, besides a rigorous revision and meticulous analysis of the morphology even architectural and cytological parameters [16,17].…”

Section: Discussionmentioning

confidence: 99%

“…The CK7 is an intermediate filament classically described in the ChRCC, with a diffuse expression in cytoplasm and membrane [4,8,11,16,17] with expression levels that fluctuate among the 63% and 100% of the cases. This pattern is found in almost all cases of our series, but sometimes is observed only in a part of the neoplasm, being negative in other areas.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Renal Oncocytoma and Cromophobe Renal Cell Carcinoma: Main Morphological Differences and Proposal of a Simple Histochemical and Immunohistochemical Panel to separate them

Ivan¹,

Gonzalo²,

Fern³

et al. 2014

J Clin Exp Pathol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Renal Oncocytoma and Cromophobe Renal Cell Carcinoma: Main Morphological Differences and Proposal of a Simple Histochemical and Immunohistochemical Panel to separate them

Ivan¹,

Gonzalo²,

Fern³

et al. 2014

J Clin Exp Pathol

View full text Add to dashboard Cite

show abstract

“…S100A1 is a member of the S100 family of calcium binding molecules, most of which are clustered on chromosome 1q21, and expressed in RCC (Teratani et al 2002). Importantly, these proteins are involved in cell cycle progression and cell differentiation (Li et al 2007) and therefore implicated in tumorigenesis, a basis for investigation of S100A1 in renal tumour subtypes.…”

Section: Discussionmentioning

confidence: 99%

“…Individual and pooled OR results are shown in a Forest plot in Figure 3.3. (Carvalho et al 2011;Kim et al 2009;Kuroda et al 2011;Li et al 2007) The pooled OR (chRCC compared to RO) was 0.01 (95% CI 0-0.03), with I 2 = 0%. Therefore, the OR of RO compared to chRCC for S100A1 staining is 100 and I 2 study heterogeneity revealed similar consistency between the effects of the 4 studies.…”

Section: S100a1mentioning

confidence: 99%

See 1 more Smart Citation

Identification of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma through molecular profiling of renal tumours

Ng¹

View full text Add to dashboard Cite

There is increasing detection of renal tumours, especially small renal masses largely due to widespread availability of radiological imaging modalities. However, imaging techniques and renal lesion biopsies cannot accurately define malignant from benign renal tumours.Therefore such indeterminate renal tumours undergo surgical resection. Unfortunately a significant proportion of resected renal tumours turn out to be benign on histopathological diagnosis. The impact of this scenario is the morbidities of unnecessary surgery and loss of valuable nephrons with the associated increased risk of chronic kidney disease and cardiovascular complications. Reduction of unnecessary surgeries would also translate into decreased costs, and allow for more efficient utilisation of health budgets.Another diagnostic dilemma faced by pathologists is the occasional difficulty in distinguishing some renal tumour subtypes, due to overlapping morphological and histological features. Differentiating malignant chromophobe renal cell carcinoma (chRCC) from benign renal oncocytoma (RO) is one such dilemma. Their correct diagnosis is crucial as prognosis, management and surveillance protocols differ between the two tumour subtypes. Therefore effective and reproducible immunohistochemistry (IHC) biomarkers need to be identified, together with novel biomarkers, through molecular profiling of these tumour subtypes.In Chapter 1, the relevant background, significance of the research topic, literature review, hypothesis and aims of this PhD research were presented. Contents of this chapter have also been published as a review article. The review article provided the clinical presentation, ii explained the diagnostic dilemma, and described the value of current molecular markers to assist in differentiation between chRCC and RO.The aims of this research project were to: 1) identify a panel of IHC biomarkers which can effectively differentiate chRCC from RO through a comprehensive literature search and meta-analysis approach, as well as using some of the research results from my laboratory; 2) analyse the molecular profiles of renal cancers via IHC and morphometry techniques using Biobank. This work involved a significant amount of time and resources throughout the PhD research project, achieved Aim 4 of the thesis, and will be a legacy of this PhD research.Chapter 3 examined the existing IHC biomarkers that have been reported as useful in differentiating chRCC from RO. A meta-analysis and systematic review was conducted in iii this chapter to assess the most effective IHC biomarkers, and it has been published. In summary, we recommended a selection from a panel of IHC biomarkers, namely, amylase α1A, Wnt-5a, FXYD2, ARPP, CD63, TGFβ1, CK7, S100A1, caveolin-1 and claudin-7 to aid in the differentiation of chRCC and RO.In Chapter 4, we investigated the molecular profiles of nuclear factor-κB (NF-κB) subunits in RCC disease. Our results represent the first and largest study to report on the IHC expression of NF-κB subunits (p65, p50, p52, cRel)...

show abstract

Malignant effusion of chromophobe renal‐cell carcinoma: Cytological and immunohistochemical findings

Pusiol

Grazia

Morichetti

et al. 2011

Diagnostic Cytopathology

View full text Add to dashboard Cite

Malignant effusions because of renal-cell carcinoma (RCC) are an unusual event and occur in patients with papillary and clear cell tumors. We have studied a 65-year-old man who underwent right renal tumorectomy, diagnosed as chromophobe RCC (pT1). After 16 months, the patient presented cough and fever. Positron emission computed tomography demonstrated extensive mediastinal lymphadenopathy. Chest radiograph showed right pleural effusion. The cytological examination of the fluid showed malignant cells. Immunohistochemistry had been performed on primary renal tumor and on cell block of pleural effusion. The renal tumor showed positivity for parvalbumin, cytokeratin (CK) 7, C-kit (CD117), E-cadherin, and RCC marker. The neoplastic cells of pleural effusion showed positive immunohistochemical staining for parvalbumin, RCC marker, pancytokeratin, epithelial membrane antigen, CK7, C-kit (CD117), E-cadherin, and CD10. They were negative for thyroid transcription factor-1, CK20, calretinin, CK5, D2-40 podoplanin, CDX2, and Wilms' tumor suppressor gene. Malignant effusion secondary to RCC is rare. In several studies, RCC had been the cause of 1-2.2% of malignant pleural fluids. Chromophobe RCC tends to be localized into the kidney and to be of nuclear grade 2 at presentation, factors that probably explain its more favorable outlook. In our case, the chromophobe RCC was asymptomatic and was discovered because abdominal pain due to stone in the gallbladder. The tumor had an unusual aggressive clinical behavior. Immunohistochemistry performed on the cell block let to establish the renal origin and the chromophobe histotype of malignant cells found in the pleural fluid.

show abstract

S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma

Abstract: S100A1 may be a potentially powerful marker to differentiate the chromophobe RCC from renal oncocytoma.

Cited by 73 publications

References 22 publications

Renal Oncocytoma and Cromophobe Renal Cell Carcinoma: Main Morphological Differences and Proposal of a Simple Histochemical and Immunohistochemical Panel to separate them

Renal Oncocytoma and Cromophobe Renal Cell Carcinoma: Main Morphological Differences and Proposal of a Simple Histochemical and Immunohistochemical Panel to separate them

Identification of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma through molecular profiling of renal tumours

Malignant effusion of chromophobe renal‐cell carcinoma: Cytological and immunohistochemical findings

Contact Info

Product

Resources

About